Ulcerative colitis

March 2, 2015March 2, 2015

Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis

News, Ulcerative colitis

Ferring Pharmaceuticals recently announced the European launch of CORTIMENT® MMX® (budesonide) to address active mild and moderate ulcerative colitis (UC) — the first and only approved oral drug for the disease. The company has ... Read more

February 24, 2015February 24, 2015

Hospira Launches First Biosimilar Monoclonal Antibody for Adult & Pediatric Crohn’s, Ulcerative Colitis In Europe

News, Ulcerative colitis

Hospira, Inc., a biotechnology company developing biosimilar therapies, has recently announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Inflectra is licensed to address several inflammatory conditions such as rheumatoid arthritis, ... Read more

February 23, 2015February 24, 2015

Infliximab in Severe Ulcerative Colitis Delays and Prevents Early Colectomy

News, Ulcerative colitis

According to a study published in the journal Clinical Gastroenterology and Hepatology, the use of infliximab in patients with acute severe ulcerative colitis reduces the need for early colectomy. In the study ... Read more

January 23, 2015January 23, 2015

Viruses Involved in Pathogenesis of IBD

Crohn's Disease, News, Ulcerative colitis

A recent pivotal study associates inflammatory bowel diseases, like Crohn’s disease (CD) and ulcerative colitis (UC), to changes in the variety of viruses in the gut. The study, entitled “Disease-Specific ... Read more

January 13, 2015January 13, 2015

Galapagos Initiates IBD Therapy Trial on Ulcerative Colitis Patients

News, Ulcerative colitis

Galapagos NV has started a phase 2 Proof-of-Concept study to evaluate a potential novel therapy, a GPR84 inhibitor called GLPG1205 that is being studied in patients who suffer from ulcerative colitis. The ... Read more

December 16, 2014December 16, 2014

UK Patients with Moderately to Severely Active UC Gain Access to New Drugs

News, Ulcerative colitis

Patients with moderately to severely active ulcerative colitis, residing in the United Kingdom, now have access to several new drugs thanks to the Final Appraisal Document (FAD) from the National Institute ... Read more

December 2, 2014December 2, 2014

Sleeping Less or More Than Recommended 7-8 Hours Per Night Linked to Ulcerative Colitis Risk

News, Ulcerative colitis

According to a recent research project published in the November issue of the journal Clinical Gastroenterology and Hepatology, higher risks of ulcerative colitis may be associated with not sleeping the recommended number ... Read more

December 1, 2014December 1, 2014

Entyvio by Takeda UK is First UC Maintenance to Receive NICE Approval

News, Ulcerative colitis

Takeda UK, a subsidiary of Japan’s leading pharmaceutical company, recently achieved a pioneering milestone when the National Institute for Health and Care Excellence (NICE) granted Entyvio® (vedolizumab) a positive provisional recommendation in the ... Read more

November 24, 2014December 1, 2014

Experimental Pediatric Ulcerative Colitis Drug Picks Up Orphan Drug Status

News, Ulcerative colitis

AvaxiaBiologics,Inc. recently announced that the US Food and Drug Administration (FDA) granted their lead experimental drug AVX-470 Orphan Drug Designation for the treatment of pediatric ulcerative colitis. The news comes after the company previously announced the results ... Read more

November 7, 2014November 7, 2014

GW Pharmaceuticals Announces Preliminary Topline Results from Phase 2a Ulcerative Colitis Trial

News, Ulcerative colitis

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® ... Read more